EXOZYMES INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
EXOZYMES INC. (EXOZ) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$1.95 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-30
- EXOZYMES INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$1.95M.
- EXOZYMES INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$1.23M.
- EXOZYMES INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$419.19K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$1.95M 10-K · filed 2026-03-30 |
| 2024-12-31 | -$1.23M 10-K · filed 2026-03-30 |
| 2023-12-31 | -$419.19K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |